Ginkgo Bioworks Holdings (DNA) Return on Capital Employed (2021 - 2026)
Ginkgo Bioworks Holdings posted quarterly Return on Capital Employed of 29.86% for Q1 2026, up 807.0% year-on-year from 3.29% in Q1 2025, and down 2.87% on a QoQ basis from 29.03% in Q4 2025.
Ginkgo Bioworks Holdings (DNA) has 6 years of Return on Capital Employed data on file, last reported at 29.86% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 807.0% year-over-year to 29.86%; the trailing twelve-month figure through Mar 2026 stood at 29.86% (up 807.0% YoY), and the FY2025 full-year result was 27.35%, up 1223.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 29.86%, down from 29.03% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 26.2% in Q2 2025 and bottomed at 202.63% in Q3 2022.
- The 5-year median for Return on Capital Employed is 51.39% (2023), against an average of 70.03%.
- The widest annual swing landed in 2022, when Return on Capital Employed slumped 19183 bps; it then surged 15656 bps in 2023.
- A 5-year view of Return on Capital Employed shows it stood at 108.71% in 2022, then soared by 53 bps to 51.39% in 2023, then gained by 18 bps to 42.34% in 2024, then jumped by 31 bps to 29.03% in 2025, then slipped by 3 bps to 29.86% in 2026.
- The last three Return on Capital Employed figures came in at 29.86% (Q1 2026), 29.03% (Q4 2025), and 31.07% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Ginkgo Bioworks Holdings | 542.03 Mn | 542.03 Mn | 16.38 Mn | -29.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.86% |
| Dec 31, 2025 | -29.03% |
| Sep 30, 2025 | -31.07% |
| Jun 30, 2025 | -26.20% |
| Mar 31, 2025 | -37.94% |
| Dec 31, 2024 | -42.34% |
| Sep 30, 2024 | -44.09% |
| Jun 30, 2024 | -60.21% |
| Mar 31, 2024 | -56.83% |
| Dec 31, 2023 | -51.39% |
| Sep 30, 2023 | -46.07% |
| Jun 30, 2023 | -58.67% |
| Mar 31, 2023 | -76.50% |
| Dec 31, 2022 | -108.71% |
| Sep 30, 2022 | -202.63% |
| Jun 30, 2022 | -160.48% |
| Mar 31, 2022 | -128.43% |
| Dec 31, 2021 | -92.53% |
| Sep 30, 2021 | -10.80% |
| Jun 30, 2021 | -12.04% |